Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to -$5.1 million.

  • Maravai Lifesciences Holdings' Change in Receivables rose 1498.84% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.3 million, marking a year-over-year increase of 7443.54%. This contributed to the annual value of -$14.4 million for FY2024, which is 8298.6% up from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Change in Receivables stood at -$5.1 million for Q3 2025, which was up 1498.84% from -$501000.0 recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Change in Receivables ranged from a high of $70.8 million in Q1 2021 and a low of -$82.4 million during Q1 2023
  • Its 5-year average for Change in Receivables is -$1.2 million, with a median of -$3.2 million in 2023.
  • Over the last 5 years, Maravai Lifesciences Holdings' Change in Receivables had its largest YoY gain of 60208.21% in 2021, and its largest YoY loss of 988284.88% in 2021.
  • Maravai Lifesciences Holdings' Change in Receivables (Quarter) stood at $51.5 million in 2021, then tumbled by 49.99% to $25.8 million in 2022, then plummeted by 65.92% to $8.8 million in 2023, then surged by 30.11% to $11.4 million in 2024, then tumbled by 144.76% to -$5.1 million in 2025.
  • Its Change in Receivables was -$5.1 million in Q3 2025, compared to -$501000.0 in Q2 2025 and -$10.2 million in Q1 2025.